Natera is trading 19.18% up now at $317.36 after its August 6, 2026 earnings release showed strong second-quarter results and management raised full-year guidance.
- Second-quarter revenue reached $752.8 million, up 37.7% year over year and exceeding expectations.
- Management raised full-year revenue guidance by $100 million at the midpoint to $2.85 billion–$2.91 billion; oncology testing volumes increased sharply.
- Positive biotech sentiment also supported the rally, with XBI reported up 2.09% during regular trading.